Certara (NASDAQ:CERT) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Certara (NASDAQ:CERT - Free Report) had its target price boosted by Robert W. Baird from $9.00 to $13.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other analysts have also recently issued reports on CERT. TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price on the stock. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Barclays lowered their price objective on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Finally, Stephens reissued an "overweight" rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Certara presently has a consensus rating of "Moderate Buy" and an average target price of $15.17.

Certara Price Performance

CERT traded down $0.40 during trading hours on Friday, hitting $13.48. The company's stock had a trading volume of 1,268,342 shares, compared to its average volume of 1,167,306. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -67.40, a P/E/G ratio of 9.29 and a beta of 1.64. The business's 50-day moving average price is $11.62 and its 200-day moving average price is $11.41. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 12 month low of $8.64 and a 12 month high of $17.94.

Hedge Funds Weigh In On Certara

A number of large investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its stake in Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares during the period. Venturi Wealth Management LLC increased its stake in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares during the period. Wells Fargo & Company MN boosted its position in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares during the period. Johnson Financial Group Inc. bought a new position in Certara in the 4th quarter worth about $47,000. Finally, Blue Trust Inc. raised its stake in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after acquiring an additional 822 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.